- At 45 minutes, response rates were significantly better than with placebo: 26.9%
with ZOMIG Tablets 5 mg vs 17.3% with placebo, increasing rapidly to 62.1% at 2
hours vs 36.0% with placebo1
- In the same controlled clinical trial, the headache response rate* with ZOMIG Tablets
2.5 mg was significantly superior to placebo at 45 minutes: 24.5% vs12.4% (P<.001),
increasing rapidly to 58.9% at 2 hours vs 34.6% with placebo(P<.001)1
- In a separate study, the 2-hour headache response rate* was achieved in 67% of patients
receiving ZOMIG Tablets 5 mg vs 34% for placebo(P<.05)2
* Defined as a reduction in headache severity, from moderate or severe to mild or
no pain.
** From a multicenter, randomized, double-blind, placebo-controlled study that included
ZOMIG Tablets 5 mg (n=482) vs placebo (n=252) for the treatment of moderate or severe
migraine.
- At 30 minutes, response rates were significantly better than with placebo: 16.5%
with ZOMIG-ZMT 5 mg vs 12.5% with placebo, increasing to 59% at 2 hours vs 30.6%
with placebo3
* Defined as a reduction in headache severity, from moderate or severe to
mild or no pain.
** From a multicenter, randomized, double-blind, placebo-controlled study that included
ZOMIG Tablets 5 mg (n=329) vs placebo (n=341) for the treatment of moderate or severe
migraine.
3
- At 10 minutes, response rates were significantly better than with placebo: 15.1%
with ZOMIG Nasal Spray 5 mg vs 9.1% with placebo, increasing rapidly to 64.8% at
2 hours vs 23.9% with placebo4
- Total symptom relief rate at 1 hour postdose was significantly higher than placebo:
14.5% with ZOMIG Nasal Spray 5 mg vs 5.1% with placebo(P<.0001)4
* Defined as a reduction in headache severity, from moderate or severe to mild or
no pain.
** From a multicenter, randomized, double-blind, parallel-group trial (n=1868) with
ZOMIG Nasal Spray 5 mg vs placebo, treating up to 2 migraine attacks of moderate
or severe intensity. The primary end point was headache response at 15 and 30 minutes,
1 and 2 hours after initial treatment. Secondary end points included pain-free rates
at all time points and 24-hour sustained headache response and pain-free rates.
9